US Pharma MarketingUCB doubles down on TCEs with $2.2bn Candid buyout
UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene. This acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE specialist, Antengene. UCB will absorb Candid’s range of T-cell engager therapies for autoimmune diseases. Credit: Na_Studio / Shutterstock.com. UCB has agreed to acquire Candid Therapeutics and its range of autoimmune and inflammatory disease-focused novel T-cell engager (TCE) candidates, bolstering the former’s pipeline amid the burgeoning growth of the immunology field. Through this buyout, UCB will hand over $2bn upfront…
UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.
Source: Pharmaceutical Technology